Transgene Biotek Ltd Stock Price Today (NSE: TRABI)
Fundamental Score
Transgene Biotek Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Transgene Biotek Ltd share price today is ₹2.52, up +0.00% on NSE/BSE as of 17 February 2026. Transgene Biotek Ltd (TRABI) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹26.14 (Cr). The 52-week high for TRABI share price is ₹N/A and the 52-week low is ₹N/A. The company has a Return on Equity (ROE) of -6.56% and a debt-to-equity ratio of 1.79.
Transgene Biotek Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Transgene Biotek Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Transgene Biotek Share Price: A Value Investor's Perspective
Within the healthcare service provider industry, consistent profitability and efficient capital allocation are crucial, especially considering the ever-evolving regulatory landscape and significant capital expenditures often required. This analysis examines the Transgene Biotek share price (₹2.16) from a conservative value investing perspective, prioritizing capital safety and long-term financial health. The absence of a Price-to-Earnings (PE) ratio immediately raises a red flag, suggesting a lack of sustained profitability. This, combined with a negative Return on Capital Employed (ROCE) of -1.75%, warrants deep scrutiny.
A negative ROCE, such as Transgene Biotek's -1.75%, significantly impairs the company's ability to build a sustainable economic moat. It indicates that the company is currently not generating sufficient returns from its invested capital to cover its cost of capital. This inhibits its competitive advantage and makes it difficult to reinvest in growth opportunities. Companies with consistently high ROCE, in contrast, typically demonstrate a stronger moat and superior long-term value creation potential.
When evaluating companies in this sector, management quality is paramount. One must ask if Transgene Biotek's management has the right strategy and execution capabilities to improve the company's financials, especially compared to its competitors like
Suraksha Diagnostic Ltd. Are there clear strategies in place to address the negative ROCE, improve profitability, and ultimately deliver value to shareholders? This is critical given Suraksha's diagnostic focus.As a value investor focused on capital safety, the current financial metrics of Transgene Biotek Ltd raise significant concerns. The lack of profitability, negative ROCE, and absence of a PE ratio suggest a high degree of financial risk. This analysis is part of an 80-parameter fundamental audit verified by Sweta Mishra and is intended for observational purposes only, reflecting a cautious assessment of the company's investment profile. This is not a recommendation to buy or sell shares.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Transgene Biotek Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of TRABI across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (-6.56%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-1.75%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-411.11%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-457.14%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-16.67%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Elevated Debt Levels (D/E: 1.79)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-1.25x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-0.42 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (23.64%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Transgene Biotek Ltd Financial Statements
Comprehensive financial data for Transgene Biotek Ltd including income statement, balance sheet and cash flow
About TRABI (Transgene Biotek Ltd)
Transgene Biotek Ltd (TRABI) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Healthcare Service Provider sector with a current market capitalisation of ₹26.14 (Cr). Transgene Biotek Ltd has delivered a Return on Equity (ROE) of -6.56% and a ROCE of -1.75%. The debt-to-equity ratio stands at 1.79, reflecting the company's capital structure. Investors tracking TRABI share price can monitor key metrics including P/E ratio, promoter holding of 23.64%, and quarterly earnings growth.
Company Details
Key Leadership
TRABI Share Price: Frequently Asked Questions
What is the current share price of Transgene Biotek Ltd (TRABI)?
As of 17 Feb 2026, 10:25 am IST, Transgene Biotek Ltd share price is ₹2.52. The TRABI stock has a market capitalisation of ₹26.14 (Cr) on NSE/BSE.
Is TRABI share price Overvalued or Undervalued?
TRABI share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 39.28x. Based on this relative valuation, the Transgene Biotek Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of TRABI share price?
The 52-week high of TRABI share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Transgene Biotek Ltd share price?
Key factors influencing TRABI share price include quarterly earnings growth (Sales Growth: -16.67%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Transgene Biotek Ltd a good stock for long-term investment?
Transgene Biotek Ltd shows a 5-year Profit Growth of 14.15% and an ROE of -6.56%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.79 before investing in TRABI shares.
How does Transgene Biotek Ltd compare with its industry peers?
Transgene Biotek Ltd competes with major peers in the Healthcare Service Provider. Investors should compare TRABI share price P/E of 0.00x and ROE of -6.56% against the industry averages to determine competitive standing.
What is the P/E ratio of TRABI and what does it mean?
TRABI share price has a P/E ratio of N/Ax compared to the industry average of 39.28x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is TRABI performing according to Bull Run's analysis?
TRABI has a Bull Run fundamental score of 0.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does TRABI belong to?
TRABI operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Transgene Biotek Ltd share price.
What is Return on Equity (ROE) and why is it important for TRABI?
TRABI has an ROE of -6.56%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Transgene Biotek Ltd generates profits from shareholders capital.
How is TRABI debt-to-equity ratio and what does it indicate?
TRABI has a debt-to-equity ratio of 1.79, which indicates high leverage that increases financial risk.
What is TRABI dividend yield and is it a good dividend stock?
TRABI offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Transgene Biotek Ltd shares.
How has TRABI share price grown over the past 5 years?
TRABI has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth 14.15%, and EPS Growth 14.15%.
What is the promoter holding in TRABI and why does it matter?
Promoters hold 23.64% of TRABI shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Transgene Biotek Ltd.
What is TRABI market capitalisation category?
TRABI has a market capitalisation of ₹26 crores, placing it in the Small-cap category.
How volatile is TRABI stock?
TRABI has a beta of N/A. A beta > 1 suggests the Transgene Biotek Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is TRABI operating profit margin trend?
TRABI has a 5-year average Operating Profit Margin (OPM) of -411.11%, indicating the company's operational efficiency.
How is TRABI quarterly performance?
Recent quarterly performance shows Transgene Biotek Ltd YoY Sales Growth of -16.67% and YoY Profit Growth of -457.14%.
What is the institutional holding pattern in TRABI?
TRABI has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Transgene Biotek Ltd stock.